K Bujko1, B Glimelius2, V Valentini3, W Michalski4, M Spalek5. 1. Department of Radiotherapy II, M. Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland. Electronic address: bujko@coi.waw.pl. 2. Department of Radiology, Oncology, and Radiation Science, Uppsala University, Uppsala, Sweden. 3. Department of Radiation Oncology, Università Cattolica S Cuore, Rome, Italy. 4. Bioinformatics and Biostatistics Unit, M. Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland. 5. Department of Radiotherapy II, M. Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland.
Abstract
BACKGROUND: There is no consensus on the role of postoperative chemotherapy in patients with rectal cancer who have received preoperative radio(chemo)therapy. MATERIALS AND METHODS: A systematic review and meta-analysis were performed of trials that used preoperative radio(chemo)therapy and randomized patients either between postoperative chemotherapy and observation or between a fluoropyrimidine only (FU-only) and a fluoropyrimidine with oxaliplatin (FU-OXA) as postoperative chemotherapy. RESULTS: Five randomized studies compared postoperative chemotherapy with observation in a total of 2398 patients. None of these trials demonstrated a statistically significant benefit of chemotherapy for OS and DFS. The pooled differences in OS and DFS did not differ statistically significantly between the chemotherapy group and the observation group. The hazard ratios (HRs) and 95% confidence intervals (CIs) were 0.95 (CI: 0.82-1.10), P = 0.49 and 0.92 (CI: 0.80-1.04), P = 0.19, respectively. In the subgroup of trials in which randomization was performed after surgery (n = 753), a statistically significant positive pooled chemotherapy effect was observed for DFS (HR = 0.79, 95% CI: 0.62-1.00, P = 0.047), but not for OS (P = 0.39). Four randomized trials compared adjuvant FU-OXA with adjuvant FU-only in 2710 patients. In two trials, the difference in DFS between groups was statistically significant in favour of FU-OXA, and in the other two trials, the difference was not significant. The pooled difference in DFS between the FU-OXA group and the FU-only group was not statistically significant: HR = 0.84 (CI: 0.66-1.06), P = 0.15. CONCLUSION: The use of postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy is not based on strong scientific evidence.
BACKGROUND: There is no consensus on the role of postoperative chemotherapy in patients with rectal cancer who have received preoperative radio(chemo)therapy. MATERIALS AND METHODS: A systematic review and meta-analysis were performed of trials that used preoperative radio(chemo)therapy and randomized patients either between postoperative chemotherapy and observation or between a fluoropyrimidine only (FU-only) and a fluoropyrimidine with oxaliplatin (FU-OXA) as postoperative chemotherapy. RESULTS: Five randomized studies compared postoperative chemotherapy with observation in a total of 2398 patients. None of these trials demonstrated a statistically significant benefit of chemotherapy for OS and DFS. The pooled differences in OS and DFS did not differ statistically significantly between the chemotherapy group and the observation group. The hazard ratios (HRs) and 95% confidence intervals (CIs) were 0.95 (CI: 0.82-1.10), P = 0.49 and 0.92 (CI: 0.80-1.04), P = 0.19, respectively. In the subgroup of trials in which randomization was performed after surgery (n = 753), a statistically significant positive pooled chemotherapy effect was observed for DFS (HR = 0.79, 95% CI: 0.62-1.00, P = 0.047), but not for OS (P = 0.39). Four randomized trials compared adjuvant FU-OXA with adjuvant FU-only in 2710 patients. In two trials, the difference in DFS between groups was statistically significant in favour of FU-OXA, and in the other two trials, the difference was not significant. The pooled difference in DFS between the FU-OXA group and the FU-only group was not statistically significant: HR = 0.84 (CI: 0.66-1.06), P = 0.15. CONCLUSION: The use of postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy is not based on strong scientific evidence.
Authors: Megan C Turner; Jeffrey E Keenan; Christel N Rushing; Brian C Gulack; Daniel P Nussbaum; Ehsan Benrashid; Terry Hyslop; John H Strickler; Christopher R Mantyh; John Migaly Journal: J Gastrointest Surg Date: 2019-01-11 Impact factor: 3.452
Authors: Jin Ho Baek; Dong Won Baek; Byung Woog Kang; Hye Jin Kim; Su Yeon Park; Jun Seok Park; Gyu Seog Choi; Jong Gwang Kim Journal: In Vivo Date: 2020 Jul-Aug Impact factor: 2.155
Authors: Benjamin Garlipp; Henry Ptok; Frank Benedix; Ronny Otto; Felix Popp; Karsten Ridwelski; Ingo Gastinger; Christoph Benckert; Hans Lippert; Christiane Bruns Journal: Langenbecks Arch Surg Date: 2016-11-09 Impact factor: 3.445
Authors: Masoud Babaei; Lina Jansen; Yesilda Balavarca; Annika Sjövall; Amanda Bos; Tony van de Velde; Michel Moreau; Gabriel Liberale; Ana Filipa Gonçalves; Maria José Bento; Cornelia M Ulrich; Petra Schrotz-King; Valery Lemmens; Bengt Glimelius; Hermann Brenner Journal: Clin Colorectal Cancer Date: 2017-09-28 Impact factor: 4.481